Goldman Sachs
TELO icon

Goldman Sachs’s Telomir Pharmaceuticals TELO Stock Holding History

Goldman Sachs’s Portfolio TELO Stock Details TELO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$13.5K Buy
+10,411
New +$13.3K ﹤0.01% 6374
2025
Q4 		– Sell
-22,636
Closed -$31.5K – 6876
2025
Q3 		$31.5K Sell
22,636
-137,958
-86% -$208K ﹤0.01% 6213
2025
Q2 		$201K Buy
160,594
+128,312
+397% +$297K ﹤0.01% 5664
2025
Q1 		$104K Sell
32,282
-18,248
-36% -$79.8K ﹤0.01% 5780
2024
Q4 		$208K Buy
+50,530
New +$238K ﹤0.01% 5630

Other funds holding TELO

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
SEM
Suncoast Equity Management Tampa, Florida $833M AUM 11.9% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
WIA
World Investment Advisors Santa Barbara, California $6.2B AUM 19.68% 1-Year Est. Return

Goldman Sachs's TELO Position: Q1 2026 in Review

Goldman Sachs opened a new position in Telomir Pharmaceuticals (TELO) in Q1 2026: 10,411 shares worth $13.5K. The stake represents ﹤0.01% of the portfolio and ranks #6374 among its holdings. This is a return to the name: Goldman Sachs previously reported a position in TELO as recently as Q3 2025.

Goldman Sachs first reported a position in TELO in Q4 2024 and has held it in 5 quarters since. The position peaked at $208K in Q4 2024. 27 funds tracked by Wall St. Rank hold TELO as of Q1 2026.

  • Goldman Sachs held 10,411 shares of Telomir Pharmaceuticals worth $13.5K as of Q1 2026.
  • Telomir Pharmaceuticals was a new Goldman Sachs position in Q1 2026.
  • Telomir Pharmaceuticals made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #6374 holding.
  • Goldman Sachs first reported a position in Telomir Pharmaceuticals in Q4 2024 and has held it in 5 quarters since.
  • Goldman Sachs's Telomir Pharmaceuticals position peaked at $208K in Q4 2024.
  • 27 funds tracked by Wall St. Rank held Telomir Pharmaceuticals as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.